Using four well-characterized uveal melanoma PDXs, we have shown that a specific Bcl-2/Bcl-XL inhibitor only had a moderate efficacy when administered alone, except in one model (MP41) with a clear dose-dependent in vivo efficacy. The gene discussed is BCL2; the disease is uveal melanoma.